The manufacturer of various eye drops, including those sold under popular brands like CVS Health Corp., Target Corp., Rite Aid Corp., and Walmart Inc., has recently issued a voluntary recall for 27 of its products. The recall was prompted by warnings from the U.S. Food and Drug Administration (FDA) regarding potential contamination.
Kilitch Healthcare India Ltd., a Mumbai-based pharmaceutical company, announced the recall on Wednesday. The affected products include those labeled with well-known retailer brands as well as Cardinal Health Inc.'s Rugby and Leader labels.
The decision to recall the products was made due to concerns related to safety after FDA investigators discovered unsanitary conditions. The affected lots have expiration dates ranging from November 2023 to September 2025. They were distributed nationwide to various retailers, wholesalers, and through the product distributor Velocity Pharma LLC.
In late October, the FDA cautioned consumers against purchasing or using these products, stating that they could lead to eye infections and potentially cause partial vision loss or even blindness. Subsequently, the retailers removed the affected products from their shelves.
Importantly, Kilitch confirmed in their statement that no adverse events associated with the recalled products have been reported.
This recall follows a recent FDA warning to Amazon.com Inc. regarding the sale of unapproved eye drops marketed for the treatment of redness, pink eye, and other conditions. CVS and Walgreens Boots Alliance Inc. also received similar warnings from the agency in September.
Rest assured, Kilitch Healthcare India Ltd. is taking proactive measures to ensure consumer safety by voluntarily recalling these potentially contaminated eye drops.
Our Latest News
SpaceX Tops Aerospace-Defense Market Valuation
Elon Musk's SpaceX achieves a valuation of $175 billion, becoming the most valuable aerospace-defense company globally. With its groundbreaking technology, it d...
SFC Energy Reports Strong Growth in Profit and Revenue
SFC Energy, the German fuel-cell specialist, reports significant growth in profit and revenue driven by sales growth in Asia and North America. The company is o...
Update on Akero Therapeutics' Lead Product Candidate
Akero Therapeutics provides an update on their lead product candidate for treating NASH, revealing impressive resolution rates and continued potential for patie...